| 3.81 0.33 (9.48%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.08 |
1-year : | 5.93 |
| Resists | First : | 4.34 |
Second : | 5.08 |
| Pivot price | 3.76  |
|||
| Supports | First : | 3.5 |
Second : | 2.99 |
| MAs | MA(5) : | 3.47 |
MA(20) : | 3.81 |
| MA(100) : | 4.84 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 47.7 |
D(3) : | 31.8 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 41.21 | Low : | 2.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMNN ] has closed below upper band by 46.2%. Bollinger Bands are 15.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.83 - 3.86 | 3.86 - 3.88 |
| Low: | 3.41 - 3.44 | 3.44 - 3.46 |
| Close: | 3.77 - 3.82 | 3.82 - 3.85 |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Wed, 31 Dec 2025
Imunon Signs Securities Purchase Agreement With Undisclosed Healthcare-Focused Institutional Investor - TradingView — Track All Markets
Tue, 30 Dec 2025
IMUNON raises $7 million in registered direct offering - Investing.com
Tue, 30 Dec 2025
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire
Mon, 29 Dec 2025
Ovarian cancer drug adds 13 months survival in early trial data - Stock Titan
Thu, 13 Nov 2025
Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 159 (K) |
| Shares Short P.Month | 214 (K) |
| EPS | -12.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.8 % |
| Return on Equity (ttm) | -233.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|